Skip to main content
. 2019 Dec 9;9:18575. doi: 10.1038/s41598-019-54960-y

Figure 4.

Figure 4

Identification and quantification of circulating tumor microemboli (CTM) in HCC patients. (A) Representative image of CTM and WBCs stained with antibodies against HCC markers and CD45. Scale bar represents 10 μm. (B) Number of CTM/mL in HCC patients grouped by TNM stage. TNM stage 0-I vs non-HCC: p = 0.2415 (ns); *stage II-IV vs non-HCC: p = 0.0195; *stage 0-I vs II-IV, p = 0.0172. (C) CTM positivity rate in TNM stages. Non-HCC vs Stage 0-I: p = 0.1235 (ns); *non-HCC vs Stage II-IV: p = 0.0118; Stage 0-I vs II-IV: p = 0.2097 (ns). (D) CTM positivity rate in BCLC stage. non-HCC vs Stage 0-A: p = 0.2621 (ns); *non-HCC vs Stage B-C: p = 0.0118; Stage 0-A vs Stage B-C: p = 0.1133 (ns).